Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

•Significantly more abaloparatide patients were all-site BMD responders versus placebo or teriparatide•At each individual anatomic site, there were significantly more abaloparatide BMD responders versus placebo•For TH, there were significantly more abaloparatide BMD responders for each threshold and timepoint versus teriparatide•For FN, at all timepoints, significantly more abaloparatide patients were >3% and >6% responders versus teriparatide•Results are consistent with the early nonvertebral fracture risk reduction with abaloparatide observed in ACTIVE